血脂康与洛伐他汀治疗高脂血症的疗效比较

Effects of Xuezhikang vs lovastatin in treating hyperlipidemia

目的 :评价血脂康与洛伐他汀对高脂血症的疗效。方法 :152例高脂血症病人分为 2组 ,血脂康组 72例 (男性 34例 ,女性 38例 ;年龄 57a±s9a)采用血脂康丸 2粒 ,po ,bid× 8wk。洛伐他汀组 80例 (男性 39例 ,女性 4 1例 ;年龄 55a± 8a)采用洛伐他汀 2 0mg ,晚餐后顿服 ,× 8wk。结果 :2组治疗后TC ,TG ,LDL C及AI[(TC -LDL C) /HDL C) ]参数值下降 ,血脂康组依次下降 2 3% ,4 0 % ,30 %及2 2 % ;洛伐他汀组依次下降 2 0 % ,38% ,2 8%及2 0 % ;2组治疗前后t检验 ,差别均有非常显著意义(P <0 .0 1) ,但组间差别无显著意义 (P >0 .0 5) ;2组均无明显不良反应。结论 :血脂康与洛伐他汀疗效相似 ,均为安全、有效的降脂药物 。

AIM: To estimate the efficacy of Xuezhikang vs lovastatin in treating hyperlipidemia. METHEDS: One hundred and fiftytwo patients with hyperlipidemia were divided into two groups. Xuezhikang group 72 patients (M 34,F 38;57 a±s9 a) were given Xuezhikang two pills, po,bid ×8 wk; 80 patients of lovastatin group (M 39,F 41,55 a±8 a) were given lovastatin 20 mg, after supper for 8 wk. RESULTS: The levels of TC,TG,LDLC and AI(TC-LDLC)/HDLC decreased with 23%,40%,30% and 22% in Xuezhikang group, with 20%,38%,28% and 20% in lovastatin group. There were very significant difference in these two groups before and after tretment (P<0.01), but not between them. CONCLUSION: These two drugs both were safe and effective in hyperlipidemia and Xuezhikang is cheaper.